Pulmonx (LUNG) Earnings Call Presentation

Company Overview - Pulmonx's 2024 revenue reached $84 million [9], demonstrating a 22% growth rate [9] - The company's gross margin stands at 74% [9] - Pulmonx holds $102 million in cash and equivalents [9] Market Opportunity - The market opportunity for severe emphysema treatment is estimated at $12 billion [5, 48] - There are approximately 15 million patients with severe emphysema in the USA [19] Zephyr Valve Treatment - The Zephyr Valve treatment process involves a 3-night hospital stay [23] - AeriSeal System has shown a 776% conversion rate from CV+ to CV- in patients [65] - AeriSeal System is estimated to expand the total addressable market by at least 20% [64] Clinical Outcomes - Zephyr valve treatment has demonstrated consistent clinical results across four randomized controlled trials (RCTs) [35] - A retrospective analysis suggests Zephyr patients have a median survival 17 years longer [39] Reimbursement and Adoption - Medicare covers patients who qualify for the Zephyr Valve procedure [46] - Over 90% of patients with commercial insurance are under a positive policy or no policy restricting access [46]